Growth hormone therapy in hypophosphatemic rickets

D. M. Wilson, Phillip Lee, A. H. Morris, E. O. Reiter, J. M. Gertner, R. Marcus, V. E. Quarmby, R. G. Rosenfeld

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

The effects of growth hormone therapy on the biochemical measures of bone metabolism were studied in 11 children aged 3.5 to 17 years who had familial hypophosphatemic rickets; five were male. Subjects were maintained on a regimen of stable doses of conventional therapy (calcitriol and phosphate). Subjects were studied at baseline receiving conventional therapy and during three sequential treatment periods: no therapy (4 weeks), growth hormone only (0.05 mg/kg per day for 4 weeks), and conventional therapy plus growth hormone (2 weeks). The nine youngest subjects were continued on a regimen of triple therapy for an additional 24 weeks. Serum phosphate averaged 0.93 ± 0.13 mmol/L (mean ± SD) at entry and decreased when the subjects were not receiving any therapy. During the 4 weeks of growth hormone only treatment, phosphate rose in all 11 subjects (0.70 ± 0.08 mmol/L to 0.83 ± 0.08 mmol/L). With triple therapy, phosphate remained higher than with no therapy. Calcitriol, osteocalcin, and parathyroid hormone increased as the subjects received growth hormone alone. Insulinlike growth factor I z scores rose significantly in response to growth hormone therapy alone. All nine subjects receiving 6 months of triple therapy increased their growth rate z scores. Exogenous growth hormone therapy may be useful in familial hypophosphatemic rickets.

Original languageEnglish (US)
Pages (from-to)1165-1170
Number of pages6
JournalAmerican Journal of Diseases of Children
Volume145
Issue number10
StatePublished - 1991
Externally publishedYes

Fingerprint

Hypophosphatemic Rickets
Growth Hormone
Therapeutics
Familial Hypophosphatemic Rickets
Phosphates
Calcitriol
Osteocalcin

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Wilson, D. M., Lee, P., Morris, A. H., Reiter, E. O., Gertner, J. M., Marcus, R., ... Rosenfeld, R. G. (1991). Growth hormone therapy in hypophosphatemic rickets. American Journal of Diseases of Children, 145(10), 1165-1170.

Growth hormone therapy in hypophosphatemic rickets. / Wilson, D. M.; Lee, Phillip; Morris, A. H.; Reiter, E. O.; Gertner, J. M.; Marcus, R.; Quarmby, V. E.; Rosenfeld, R. G.

In: American Journal of Diseases of Children, Vol. 145, No. 10, 1991, p. 1165-1170.

Research output: Contribution to journalArticle

Wilson, DM, Lee, P, Morris, AH, Reiter, EO, Gertner, JM, Marcus, R, Quarmby, VE & Rosenfeld, RG 1991, 'Growth hormone therapy in hypophosphatemic rickets', American Journal of Diseases of Children, vol. 145, no. 10, pp. 1165-1170.
Wilson DM, Lee P, Morris AH, Reiter EO, Gertner JM, Marcus R et al. Growth hormone therapy in hypophosphatemic rickets. American Journal of Diseases of Children. 1991;145(10):1165-1170.
Wilson, D. M. ; Lee, Phillip ; Morris, A. H. ; Reiter, E. O. ; Gertner, J. M. ; Marcus, R. ; Quarmby, V. E. ; Rosenfeld, R. G. / Growth hormone therapy in hypophosphatemic rickets. In: American Journal of Diseases of Children. 1991 ; Vol. 145, No. 10. pp. 1165-1170.
@article{4f0388cbe51445958a2a796404366c3f,
title = "Growth hormone therapy in hypophosphatemic rickets",
abstract = "The effects of growth hormone therapy on the biochemical measures of bone metabolism were studied in 11 children aged 3.5 to 17 years who had familial hypophosphatemic rickets; five were male. Subjects were maintained on a regimen of stable doses of conventional therapy (calcitriol and phosphate). Subjects were studied at baseline receiving conventional therapy and during three sequential treatment periods: no therapy (4 weeks), growth hormone only (0.05 mg/kg per day for 4 weeks), and conventional therapy plus growth hormone (2 weeks). The nine youngest subjects were continued on a regimen of triple therapy for an additional 24 weeks. Serum phosphate averaged 0.93 ± 0.13 mmol/L (mean ± SD) at entry and decreased when the subjects were not receiving any therapy. During the 4 weeks of growth hormone only treatment, phosphate rose in all 11 subjects (0.70 ± 0.08 mmol/L to 0.83 ± 0.08 mmol/L). With triple therapy, phosphate remained higher than with no therapy. Calcitriol, osteocalcin, and parathyroid hormone increased as the subjects received growth hormone alone. Insulinlike growth factor I z scores rose significantly in response to growth hormone therapy alone. All nine subjects receiving 6 months of triple therapy increased their growth rate z scores. Exogenous growth hormone therapy may be useful in familial hypophosphatemic rickets.",
author = "Wilson, {D. M.} and Phillip Lee and Morris, {A. H.} and Reiter, {E. O.} and Gertner, {J. M.} and R. Marcus and Quarmby, {V. E.} and Rosenfeld, {R. G.}",
year = "1991",
language = "English (US)",
volume = "145",
pages = "1165--1170",
journal = "JAMA Pediatrics",
issn = "2168-6203",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Growth hormone therapy in hypophosphatemic rickets

AU - Wilson, D. M.

AU - Lee, Phillip

AU - Morris, A. H.

AU - Reiter, E. O.

AU - Gertner, J. M.

AU - Marcus, R.

AU - Quarmby, V. E.

AU - Rosenfeld, R. G.

PY - 1991

Y1 - 1991

N2 - The effects of growth hormone therapy on the biochemical measures of bone metabolism were studied in 11 children aged 3.5 to 17 years who had familial hypophosphatemic rickets; five were male. Subjects were maintained on a regimen of stable doses of conventional therapy (calcitriol and phosphate). Subjects were studied at baseline receiving conventional therapy and during three sequential treatment periods: no therapy (4 weeks), growth hormone only (0.05 mg/kg per day for 4 weeks), and conventional therapy plus growth hormone (2 weeks). The nine youngest subjects were continued on a regimen of triple therapy for an additional 24 weeks. Serum phosphate averaged 0.93 ± 0.13 mmol/L (mean ± SD) at entry and decreased when the subjects were not receiving any therapy. During the 4 weeks of growth hormone only treatment, phosphate rose in all 11 subjects (0.70 ± 0.08 mmol/L to 0.83 ± 0.08 mmol/L). With triple therapy, phosphate remained higher than with no therapy. Calcitriol, osteocalcin, and parathyroid hormone increased as the subjects received growth hormone alone. Insulinlike growth factor I z scores rose significantly in response to growth hormone therapy alone. All nine subjects receiving 6 months of triple therapy increased their growth rate z scores. Exogenous growth hormone therapy may be useful in familial hypophosphatemic rickets.

AB - The effects of growth hormone therapy on the biochemical measures of bone metabolism were studied in 11 children aged 3.5 to 17 years who had familial hypophosphatemic rickets; five were male. Subjects were maintained on a regimen of stable doses of conventional therapy (calcitriol and phosphate). Subjects were studied at baseline receiving conventional therapy and during three sequential treatment periods: no therapy (4 weeks), growth hormone only (0.05 mg/kg per day for 4 weeks), and conventional therapy plus growth hormone (2 weeks). The nine youngest subjects were continued on a regimen of triple therapy for an additional 24 weeks. Serum phosphate averaged 0.93 ± 0.13 mmol/L (mean ± SD) at entry and decreased when the subjects were not receiving any therapy. During the 4 weeks of growth hormone only treatment, phosphate rose in all 11 subjects (0.70 ± 0.08 mmol/L to 0.83 ± 0.08 mmol/L). With triple therapy, phosphate remained higher than with no therapy. Calcitriol, osteocalcin, and parathyroid hormone increased as the subjects received growth hormone alone. Insulinlike growth factor I z scores rose significantly in response to growth hormone therapy alone. All nine subjects receiving 6 months of triple therapy increased their growth rate z scores. Exogenous growth hormone therapy may be useful in familial hypophosphatemic rickets.

UR - http://www.scopus.com/inward/record.url?scp=0025939791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025939791&partnerID=8YFLogxK

M3 - Article

C2 - 1928011

AN - SCOPUS:0025939791

VL - 145

SP - 1165

EP - 1170

JO - JAMA Pediatrics

JF - JAMA Pediatrics

SN - 2168-6203

IS - 10

ER -